Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 17/20 | 0.81 |
| ▸ | SLC5A1 | P13866 | 11/20 | 0.81 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14634631 | 1.00 | SLC5A2 (0.81) | SLC5A2SLC5A1NPC1RAB9AACHE | |
| SCHEMBL14634632 | 0.93 | SLC5A2 (0.93) | SLC5A2SLC5A1NPC1RAB9AACHE | |
| SCHEMBL14634627 | 0.93 | SLC5A2 (0.93) | SLC5A2SLC5A1NPC1RAB9AACHE | |
| SCHEMBL874080 | 0.93 | SLC5A2 (0.93) | SLC5A2SLC5A1NPC1RAB9AACHE | |
| SCHEMBL4355551 | 0.92 | SLC5A2 (0.81) | SLC5A2SLC5A1NPC1RAB9AACHE | |
| SCHEMBL4355545 | 0.92 | SLC5A2 (0.81) | SLC5A2SLC5A1NPC1RAB9AACHE | |
| SCHEMBL4360297 | 0.91 | SLC5A2 (0.86) | SLC5A2SLC5A1NPC1RAB9AACHE | |
| SCHEMBL4359339 | 0.91 | SLC5A2 (0.79) | SLC5A2SLC5A1NPC1RAB9AACHE | |
| SCHEMBL4359333 | 0.91 | SLC5A2 (0.79) | SLC5A2SLC5A1NPC1RAB9AACHE | |
| SCHEMBL4360304 | 0.91 | SLC5A2 (0.86) | SLC5A2SLC5A1NPC1RAB9AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022117893-A2 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2022-06-09 | — | — | WO | claimed |
| WO-2022117893-A2 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2022-06-09 | — | — | WO | disclosed |